Some empirical notes on the epo epidemic in professional cycling

Research Quarterly for Exercise and Sport

Volumn 82, Issue 4, 2011, Pages 740-754

  Lodewijkx, Hein F M ^a   Brouwer, Bram ^a  

^a OPEN UNIVERSITY OF THE NETHERLANDS   (Netherlands)

Author keywords

Doping; Historical records of European cycling; Sport performance; Stage races

Indexed keywords

ERYTHROPOIETIN;

ANALYSIS OF VARIANCE; ARTICLE; ATHLETIC PERFORMANCE; BICYCLE; DOPING; DRUG EFFECT; ENDURANCE; HUMAN; MALE; PHYSIOLOGY;

ANALYSIS OF VARIANCE; ATHLETIC PERFORMANCE; BICYCLING; DOPING IN SPORTS; ERYTHROPOIETIN; HUMANS; MALE; PHYSICAL ENDURANCE;

EID: 83255186240     PISSN: 02701367     EISSN: 21683824     Source Type: Journal    
DOI: 10.1080/02701367.2011.10599811     Document Type: Article

References (48)

1. Albergotti, R., & O’Connell, V. (2010, May 7). Blood brothers. The Wall Street Journal, 15–17.
2. Audran, M., Gareau, R., Matecki, S., Durand, F., Chenard, C., Sicart, M.-T.,…Bressole, F. (1999). Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Medicine & Science in Sports & Exercise, 31, 639–645.
3. Birkeland, K. I., Stray-Gundersen, J., Hemmersbach, P., Hallen, J., Haug, E., & Bahr, R. (2000). Effect of rhEPO administration on serum levels in sTfR and cycling performance. Medicine & Science in Sports & Exercise, 32, 1238–1243.
4. Brewer, B. F. (2002). Commercialization in professional cycling 1950–2001: Institutional transformations and the rationalization of “doping.” Sociology of Sport Journal, 19, 276–301.
5. Brouwer, B., Lodewijkx, H. F. M., & Kuipers, H. (2009). Doping confessions of cyclists revisited. [Dopingbekentenissen langs de meetlat]. Sportpsychologie Bulletin, 20, 24–37.
6. Catlin, D. H., Hatton, C. K., & Lasne, F. (2006). Abuse of recombinant erythropoietins by athletes. In G. Molineux, M. A. Foote, & S. G. Elliott (Eds.), Erythropoietins anderythropoiesis (pp. 205–228). Basel, Switzerland: Birkhäuser Verlag.
7. Connes, P., Perrey, S., Varray, A., Prefaut, C., & Caillaud, C. (2003). Faster oxygen uptake kinetics at the onset of submaximal cycling exercise following 4 weeks recombinant human erythropoietin(r-HuEPO) treatment. European Journal of Physiology, 447, 231–238.
8. Dimeo, P. (2007). A history of drug use in sport 1876–1976. New York: Routledge/Taylor & Francis Group.
9. Ducrot, M. (1987). Dispatches from the Tour de France. [Berichten uit de Tour de France]. Amsterdam: Thomas Rap.
10. Ejnes, G., Bouvet, P., Dufourq, R., Laget, S., & Schaller, G. (2002). Tour de France 100 years. (Vol. I, II, and III). [Tour de France 100 ans (Vol. I, II, and III)]. Paris: L’Equipe.
11. Ekblom, B., & Berglund, B. (1991). Effect of erythropoietin administration on maximal aerobic power. Scandinavian Journal of Medicine and Science in Sports, 1, 88–93.
12. Festinger, L. (1954). A theory of social comparison. Human Relations, 7, 117–140.
13. Field, A. (2005). Discovering statistics using SPSS (2nd ed.) London: Sage.
14. Fotheringham, W. (2009). Fallen angel: The passion of Fausto Coppi. London: Yellow Jersey Press/Random House.
15. Friedl, K. E. (2005). Effects of testosterone and related androgens on athletic performance in men. In W. J. Kraemer & A. D. Rogol (Eds.), The endocrine system in sports and exercise (pp. 525–543). Oxford, UK: Blackwell.
16. Gore, C. J., Hahn, G., Burge, C. M., & Telford, R. D. (1997). VO2max and the hemoglobin mass of trained athletes during high intensity training. International Journal of Sports Medicine, 18, 477–482.
17. Gregor, R. J., Conconi, F., & Broker, J. P. (2000). Biomechanics of road cycling. In R. J. Gregor & F. Conconi (Eds.), Handbook of sports medicine and science: Road cycling (pp. 18–39). Oxford, UK: Blackwell.
18. Hoberman, J. (1992). Mortal engines: The science of performance and the dehumanization of sport. New York: The Free Press.
19. Hoberman, J. (2005). Testosterone dreams: Rejuvenation, aphrodisia, doping. Berkeley, CA: University of California Press.
20. Hopkins, W. G. (2004). How to interpret changes in an athletic performance test. Sportscience, 8, 1–7. Retrieved July 20, 2010, from http://www.sportsci.org/jour/04/wghtests.htm
21. Hopkins, W. G., Schabort, E.J., & Hawley, J. A. (2001). Reliability of power in physical performance tests. Sports Medicine, 31, 211–234.
22. Jelkmann, W. (2000). Use of recombinant human erythropoietin as an anti-anemic and performance-enhancing drug. Current Pharmaceutical Biotechnology, 1, 11–31.
23. Johnson, A. T. (2007). Biomechanics and exercise physiology: Quantitative modeling. New York: CRC Press/Taylor & Francis Group.
24. Joyner, M. J., & Coyle, E. F. (2008). Endurance exercise performance: The physiology of champions. Journal of Physiology, 586(1), 35–44.
25. Kirby, K. N. (1993). Advanced data analysis with SYSTAT. New York: Van Nostrand Reinhold.
26. Kuipers, H. (2006). Putative effects of doping in cycling. [Ver-meende effecten van doping in de wielersport]. Nederlands Tijdschrift voor Geneeskunde, 150, 2643–2645.
27. Kuipers, H., Moran, J., Dubravcic-Simunjak, S., Mitchell, D. W., Shobe, J., Sakai, H., & Ambartsumov, R. (2007). Hemoglobin level in elite speed skaters from 2000 up to 2005 and its relationship with competitive results. International Journal of Sports Medicine, 28, 16–20.
28. Kuipers, H., Moran, J., Mitchell, D., Shobe, J., Dubravcic-Simunjak, S., Sakai, H., & Ambartsumov, R. (2007). Hemoglobin levels and athletic performance in elite speed skaters during the Olympic season 2006. Clinical Journal of Sports Medicine, 17, 135–139.
29. Lasne, F. (2009). Erythropoietin doping: Detection in urine. In J. L. Fourcroy (Ed.), Pharmacology, doping and sports (pp. 107–124). London: Routledge.
30. Londres, A. (2002). Convicts of the road. [Candide chez les forçats]. In G. Ejnès, P. Bouvet, R. Dufourq, S. Laget, & G. Schaller (Eds.), Tour de France 100 ans (Vol. I, p. 149). Paris: L’Equipe. (Original work published in 1924)
31. Lucia, A., Earnest, C., & Arribas, C. (2003). The Tour de France: A physiological review. Scandinavian Journal of Medicine and Science in Sports, 13, 275–283.
32. Magnier, D., Picq, P., Debreilly, M., Zingoni, P., Haffreingue, H., & Bey, J.-L. (2009). Cycling remembered. [Memoires du cyclisme]. Retrieved December 19, 2009, from http://www.memoire-du-cyclisme.net
33. Maso, B. (2003). We were all gods. The Tour of 1948. [Wij waren allemaalgoden. De Tour van 1948]. Amsterdam: Atlas.
34. Maso, B. (2005). The sweat of the gods. Norwich, UK: Mousehold Press.
35. Nelissen, J. (1995). The bible of the Tour de France. [De bijbel van de Tour de France]. Maastricht, The Netherlands: WIN Publiciteit.
36. Ninot, G., Connes, P., & Caillaud, C. (2006). Effects of recombinant human erythropoietin injections on physical self in endurance athletes. Journal of Sports Sciences, 24, 383–391.
37. Noakes, T. D. (2000). Physiological models to understand exercise fatigue and the adaptations that predict or enhance athletic performance. Scandinavian Journal of Medicine and Science in Sports, 10, 123–145.
38. Robach, P., Calbet, J. A. L., Thomsen, J. J., Boushel, R., Mollard, P., Rasmussen, P., & Lundby, C. (2008). The ergogenic effect of recombinant human erythropoietin on VO2max depends on the severity of arterial hypoxemia. PLoS ONE, 3(8): e2996. doi:10.1371/journal.pone.0002996
39. Sawka, M. N., Joyner, M. J., Miles, D. S., Roberson, R J., Spriet, L. L., & Young, A. J. (1996). The use of blood doping as an ergogenic aid. Medicine & Science in Sports & Exercise, 28, 127–134.
40. Stray-Gundersen, J., Videman, T., & Penttila, I. (2003). Abnormal hematologic profiles in elite cross-county skiers: Blood doping or? Clinical Journal of Sports Medicine, 13, 132–137.
41. Tabachnick, B. G., & Fidell, L. S. (2001). Using multivariate statistics. Boston: Allyn & Bacon.
42. Tokish, J. M., Kocher, M. S., & Hawkins, R. J. (2004). Ergogenic aids: A review of basic science, performance, side effects, and status in sports. American Journal of Sports Medicine, 32, 1543–1553.
43. van Ingen Schenau, G. J. (1985). Speed: A balance between exercise and friction. [Snelheid: Een evenwicht tussen inspanning en wnjving]. In J. P. Clarijs & G. J. van Ingen Schenau (Eds.), Wielrennen (pp. 39–67). Ghent, Belgium: De Tijdstroom.
44. Varlet-Marie, E., Gaudard, E., Audran, M., & Bressolle, F. (2003). Pharmacokinetics/pharmacodynamics of recombinant human erythropoietins in doping control. Sports Medicine, 33, 301–315.
45. Verbruggen, H. (2001). The EPO epidemic in sport. Bloodline Reviews, 1, 3–4.
46. Voet, W. (2001). Breakingthechain. London: YellowJersey Press/ Random House.
47. Wilkerson, D. P., Rittweger, J., Berger, N. J., Naish, P. F., & Jones, A. M. (2005). Influence of recombinant human erythropoietin treatment on pulmonary O2 uptake kinetics during exercise in humans. Journal of Physiology, 568, 639–652.
48. World Anti-Doping Agency. (2010). World Anti-Doping Agency, prohibited list. Retrieved July 18, 2010, from http://www. wada-ama.org/en/World-Anti-Doping-Program/Sports- and-Anti-Doping-Organizations/International-Standards/ Prohibited-List